Browse articles from EyeWorld.org related to IOLs. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Presbyopia-correcting eye drop receives FDA approval
➤ Four-year, first-in-human results for IOL-based drug delivery system
➤ FDA approves new treatment for thyroid eye disease
➤ New registry establishes baseline for interventional glaucoma procedures in the U.S.
➤ Phase 3 study for DME does not meet primary endpoint, triggering strategic decisions
➤ Company news
➤ ASCRS news and events
➤ EyeWorld article of the week
➤ Phase 4 results for iDose TR
➤ Phase 3 extension study showcases positive results with epithelium-on crosslinking
➤ 6-month results from bio-reinforced canaloplasty procedure for glaucoma
➤ Dosing update in Phase 1 study evaluating mRNA treatment of optic atrophy
➤ Enrollment complete in Phase 2a study for geographic atrophy
➤ IND amendment submitted to FDA to expand indication for product candidate
➤ Complimentary access to video journal
➤ Company news
➤ ASCRS news and events
➤ EyeWorld article of the week
Residual refractive error can leave a patient less than satisfied after ophthalmic surgery. Lens choice can influence this, though continual study and innovation have begun to take it into account, with some lenses now being more forgiving to residual refractive error. EyeWorld spoke with ophthalmologists who have researched this.
When it comes to true presbyopia-correcting lenses, there are two main categories: extended depth of field and full depth of field. Both of these categories have new additions (at least new to the U.S. market), and surgeons already using these lenses are excited about the results.
➤ FDA approves ‘world’s first’ spiral IOL platform
➤ Company to submit formal appeal after FDA’s denial of dry eye disease NDA
➤ FDA to hold Advisory Committee meeting for low-dose atropine treatment for myopia
➤ Positive results in Phase 3 trial for AMD treatment
➤ Phase 3 trial investigating DME treatment begins
➤ ASCRS news and events
➤ EyeWorld article of the week
While many surgeons reserve the Light Adjustable Lens (LAL, RxSight) for post-LASIK, post-PRK, and difficult eyes, others are increasingly using it in routine cataract patients, finding that the ability to set refraction postop with patient input offers advantages. Three physicians shared their experiences and perspectives on this.
➤ Enrollment complete in pivotal trial for first-in-class regenerative cell therapy
➤ First patients dosed in Phase 3 trial for TED treatment
➤ 6-month results with virtual aperture IOL
➤ Company news
➤ ASCRS news and events
➤ EyeWorld article of the week
➤ AMA classifies myopia as a disease
➤ Report marks shift in refractive surgery trends
➤ Patient dosing begins in Phase 2 trial for oral DME therapy
➤ ASCRS news and events
➤ EyeWorld article of the week
➤ Launch of biosimilar for retinal disease
➤ New partnership to advance perimetry program
➤ Approval of thyroid eye disease treatment
➤ Collaboration to develop adjustable PCIOLs
➤ Progress in treatment for neuropathic corneal pain
➤ Priority review for thyroid eye disease treatment
➤ RMAT designation granted to investigational magnetic human corneal endothelial cell therapy
➤ Complimentary access to video journal
➤ ASCRS news and events
➤ EyeWorld article of the week
Recently, visual simulator tools are becoming available within ophthalmology to help demonstrate the vision of certain lenses and aid patients in understanding the options available. EyeWorld spoke to several doctors about the utility of this technology, as well as about specific products.
